Atamestane

Drug Profile

Atamestane

Alternative Names: Biomed 777; SH 489; ZK 95639

Latest Information Update: 11 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Intarcia Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Breast cancer

Most Recent Events

  • 31 Jan 2005 Intarcia Therapeutics has completed enrolment in the first phase III trial (Biomed 777-CLP-29 study) for Breast cancer in the US, Canada, Russia and Ukraine
  • 31 Dec 2004 Intarcia Therapeutics has initiated enrolment in the CAT study for Breast cancer in the US and Europe
  • 02 Dec 2004 This compound is still in active development for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top